2 Dividend Stocks to Buy Hand Over Fist in November
Which healthcare stock can dividend investors safely buy? Let's consider two excellent options: AbbVie (NYSE: ABBV) and Amgen (NASDAQ: AMGN).
GlobalData on MSN6d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...
BioPharma Dive6d
Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...
FiercePharma5d
AstraZeneca, Amgen's Tezspire scores in rhinosinusitis study
Six months after Amgen and AstraZeneca reported promising results for Tezspire (t | A phase 3 study has shown that ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
What Analysts Are Saying About Amgen Stock
Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...
BioSpace3d
AstraZeneca, Amgen Claim Late-Stage Win in Chronic Rhinosinusitis but Analyst Flags ‘Regulatory Risk’
The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...
Zacks.com on MSN1d
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US
Alliance revenues included $361 million from Daiichi Sankyo for Enhertu and $123 million of AstraZeneca’s share of gross ...
pharmaphorum2y
AstraZeneca's Tezspire for severe asthma gets green light in EU
Tezspire (tezepelumab) has been cleared for use in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal ...
AstraZeneca’s Tezspire Shows Promise in Phase III Trial
AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Tezspire has shown promising results in the Phase III WAYPOINT trial, ...
Yahoo Finance6d
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
November 08, 2024--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that ...